Altering the Course of Small Cell Lung Cancer: Targeting Cancer Stem Cells via LSD1 Inhibition  C. Allison Stewart, Lauren Averett Byers  Cancer Cell  Volume 28, Issue 1, Pages 4-6 (July 2015) DOI: 10.1016/j.ccell.2015.06.011 Copyright © 2015 Elsevier Inc. Terms and Conditions

Figure 1 Proposed DNA Hypomethylation Signature to Predict SCLC Sensitivity (A) A signature of 45 differentially methylated CpGs was associated with in vitro sensitivity to the LSD1 inhibitor GSK2879552. To test the performance of the methylation signature, patient-derived xenografts (PDXs) were scored to predict drug response. Two PDXs with positive methylation signature scores responded to GSK2879552, whereas a PDX with a negative score was resistant. (B) Clinical schema of proposed mechanism of GSK2879552 in a biomarker selected SCLC patient population. Following an initial treatment period with chemotherapy, treatment of stem-cell enriched residual SCLC tumor leads to further regression and disease control. Cancer Cell 2015 28, 4-6DOI: (10.1016/j.ccell.2015.06.011) Copyright © 2015 Elsevier Inc. Terms and Conditions